New Liposomal Cytarabine Formulation in CSF
Casado, P.; Torreira, C.; Oujo, E.; Esteban, P.; Albo, C.; Diaz, R.; M.A. Andrade
Clinical Laboratory 56(1-2): 69-70
2010
ISSN/ISBN: 1433-6510 PMID: 20380362 Document Number: 13712
Document emailed within 1 workday
Related Documents
Silvani, A. 2007: Experience with the intrathecal use of liposomal cytarabine at the Besta Institute Tumori 93(3): Suppl. 6-8Slifirski, P.; Szelejewski, W.ła.; Grynkiewicz, G.; Gubernator, J.; Kozubek, A. 2003: Liposomal formulation of idarubicin Acta Poloniae Pharmaceutica 60(2): 138-140
Stevens, P.J.; Lee, R.J. 2003: Formulation kit for liposomal doxorubicin composed of lyophilized liposomes Anticancer Research 23(1a): 439-442
Boswell, G.W.; Bekersky, I.; Buell, D.; Hiles, R.; Walsh, T.J. 1998: Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats Antimicrobial Agents and ChemoTherapy 42(2): 263-268
Arif, K.; Ejaj, A.; Maroof, A.; Azmat, A.K.; Arun, C.; Fatima, N.; Gatoo, M.A.; Owais, M. 2009: Protective effect of liposomal formulation of tuftsin (a naturally occurring tetrapeptide) against cyclophosphamide-induced genotoxicity and oxidative stress in mice Indian Journal of Biochemistry and Biophysics 46(1): 45-52
Iwaszkiewicz, K.S.; Hua, S. 2014: Development of an effective topical liposomal formulation for localized analgesia and anti-inflammatory actions in the Complete Freund's Adjuvant rodent model of acute inflammatory pain Pain Physician 17(6): E719-E735
Mandelli, F.; Petti, M.C.; Ardia, A.; Di Pietro, N.; Di Raimondo, F.; Ganzina, F.; Falconi, E.; Geraci, E.; Ladogana, S.; Latagliata, R. 1991: A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA European Journal of Cancer 27(6): 750-755
Masaoka, T.; Ogawa, M.; Yamada, K.; Kimura, K.; Ohhashi, Y. 1993: A late phase Ii comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(13): 1995-2005
2003: Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects Prescrire International 12(67): 179
2002: Tobramycin for nebulisation: new formulation. A high price for a small improvement in formulation Prescrire International 11(62): 177-178
Wang, Y.J.; Leesman, G.D.; Lipstein, M.E.; Basch, H.I.; Monkhouse, D.C. 1984: Optimization of autoclave cycles and selection of formulation for parenteral products, Part III: Effect of formulation variables on sporicidal kinetics Journal of parenteral science and technology: a publication of the Parenteral Drug Association 38(2): 78-82
Soni, S.D.; Tench, D.; Ashwood, T.J.; Movin, G. 1990: Pharmacokinetics of an oral controlled release formulation of remoxipride: a double-blind, crossover comparison with conventional formulation in chronic schizophrenics Acta Psychiatrica Scandinavica. Supplementum 358: 45-47
2003: Paracetamol for injection: new formulation. New formulation: why so widely used? Prescrire International 12(67): 178
Vens-Cappell, B.; Hilgenstock, C.; Gellert, M.; Kühle, K.; Reifferscheid, I.; Winckler, P.; Bührens, K.G. 1993: Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration Arzneimittel-Forschung 43(3): 346-350
Jehl, F.; Klossek, J.M.; Peynegre, R.; Serrano, E.; Castillo, L.; Bobin, S.; Desprez, D.; Renault, C.; Neel, V.; Rouffiac, E.; Borie, C. 2002: Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily Presse Medicale 31(34): 1596-1603
Scheidel, B.; Blume, H.; Walter, K.; von Nieciecki, A.; Babej-Dölle, R.M. 1993: Biological availability of gastric juice-resistant coated diclofenac preparations. 1. Bioavailability study following a single administration of a multiple-unit formulation in comparison with a single-unit formulation Arzneimittel-Forschung 43(11): 1211-1215
Eridani, S. 1972: Cytarabine: mechanism of action and clinical application Haematologica 57(7): 341-358
Nishi, T.; Funasako, M.; Hata, N.; Andoh, K.; Itoh, Y.; Ono, H.; Itoh, K.; Sato, Y.; Sato, H.; Taniji, M.; Nakai, S.; Ueda, A.; Fujimoto, H.; Ohata, M. 1996: Five cases of myelodysplastic syndrome treated with cytarabine ocfosfate Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(10): 1331-1334
Fadl, T.A.; Hasegawa, T.; Youssef, A.F.; Farag, H.H.; Omar, F.A.; Kawaguchi, T. 1995: Synthesis and investigation of N4-substituted cytarabine derivatives as prodrugs Die Pharmazie 50(6): 382-387
Arai, T.; Narimiya, S.; Hayakawa, K.; Takaya, T.; Toshima, S.; Araki, M.; Uchida, A.; Yoshimi, N.; Shibuya, C.; Yasuda, Y. 1994: Successful treatment of myelodysplastic syndrome with cytarabine ocfosfate Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(7): 1085-1088